Peptide LexiconAll compounds

Dactinomycin (Actinomycin D): The Chromopeptide Chemotherapy — What It Is, How It Blocks RNA and What Its Trials Showed

Dactinomycin, also called actinomycin D, is a chromopeptide antibiotic made by Streptomyces bacteria: two rings of five amino acids attached to a flat, coloured ring system, binding DNA and blocking RNA synthesis. It has been US chemotherapy since the 1960s for Wilms tumour, rhabdomyosarcoma, Ewing sarcoma, testicular cancer and gestational trophoblastic neoplasia. Today only generics are listed.

FDA-approved chemotherapyChromopeptide antitumour antibioticBrand Cosmegen discontinued; generics only in the US

Caroline S · Published 2026-11-19

Length

C62H86N12O16, molecular weight 1,255.4 (PubChem CID 457193; label 1,255.42)

Sequence

Not a linear chain: two cyclic pentapeptide lactones attached to a phenoxazinone chromophore, per PubChem's structure name

Origin

Produced by the soil bacterium Streptomyces parvullus (label). Brand Cosmegen, NDA 050682, now discontinued; oldest submission on that file dated 1964-12-10 (Drugs@FDA)

Last reviewed

2026-11-19

What is it good for?

Killing fast-dividing cancer cells by binding DNA and stopping RNA from being made. The label lists Wilms tumour, rhabdomyosarcoma, Ewing sarcoma and metastatic nonseminomatous testicular cancer as part of combination chemotherapy, gestational trophoblastic neoplasia alone or in combination, and regional limb or pelvic perfusion with melphalan. It is given intravenously by cancer specialists.

Illustration: A deep green conical flask on a white laboratory bench.
Illustration

What it is

Dactinomycin is a chromopeptide antibiotic: a flat, coloured ring system (a phenoxazinone) carrying two identical rings of five amino acids, each closed into a lactone. That description is PubChem's structure name for CID 457193, and the label calls it "an actinomycin" produced by Streptomyces parvullus. It is the best-known member of the actinomycins, which is why it is also called actinomycin D.

Property Value Source
Formula C62H86N12O16 PubChem CID 457193; label
Molecular weight 1,255.42 Da Label
Structure Phenoxazinone core + two cyclic pentapeptide lactones PubChem structure name
Producer Streptomyces parvullus Label
Vial 500 mcg dactinomycin + 20 mg mannitol, lyophilised Label

How it acts. The label's summary is that it "binds DNA and inhibits RNA synthesis"; cells that are dividing fast depend most on making RNA, which is why it is used against cancers. Its nearest relative in the library is bleomycin, another peptide-derived antibiotic from Streptomyces, which breaks DNA rather than blocking RNA. Other peptide-based cancer drugs in the library work on the proteasome instead: bortezomib and carfilzomib.

What the label covers

Per the Meitheal label (effective 2020-11-13), dactinomycin is indicated for:

Use How the label places it Example label dose
Wilms tumour Multi-phase combination chemotherapy, adult and paediatric 45 mcg/kg IV every 3–6 weeks, up to 26 weeks
Rhabdomyosarcoma Combination chemotherapy 15 mcg/kg IV daily × 5, every 3–9 weeks
Ewing sarcoma Combination chemotherapy 1,250 mcg/m² IV every 3 weeks
Metastatic nonseminomatous testicular cancer With cisplatin-based chemotherapy 1,000 mcg/m² IV every 3 weeks
Gestational trophoblastic neoplasia Single agent or combination 12 mcg/kg IV daily × 5 (low risk)
Regional perfusion With melphalan, lower or upper limb or pelvis 50 or 35 mcg/kg once

These are the label's figures, reported as written; the regimen for any patient is set by an oncology team.

The label's pharmacokinetic data rest on three people. Its distribution and excretion section comes from radiolabelled dactinomycin given to three adults with malignant melanoma: it concentrated in nucleated cells, did not cross the blood–brain barrier, and about 30% was recovered in urine and faeces within a week.

What the trials showed

  • Gestational trophoblastic neoplasia. In GOG-0174, 240 women were enrolled and 216 eligible; biweekly IV dactinomycin 1.25 mg/m² gave complete responses in 70% against 53% for weekly IM methotrexate 30 mg/m² (P = .01). Both regimens were less effective at WHO risk score 5–6 or with choriocarcinoma (the abstract reports complete responses of 9% and 42%) (Osborne et al. 2011, PMID 21263100).
  • Wilms tumour. NWTS-4 randomised 1,687 children to single-dose "pulse-intensive" or 5-day divided-dose dactinomycin (with vincristine, and doxorubicin in high-risk disease). Two-year relapse-free survival was 91.3% v 91.4% in low-risk and 87.3% v 90.0% in high-risk patients; the authors recommended the single-dose schedule as the new standard, citing equal efficacy, less severe blood toxicity and fewer visits (Green et al. 1998, PMID 9440748).

Risks the label lists

Secondary cancers including leukaemia; severe or fatal hepatic veno-occlusive disease, with higher risk under age 4 or with radiotherapy; extravasation injury; myelosuppression; severe mucocutaneous reactions; renal toxicity and hepatotoxicity; potentiation of radiation toxicity and radiation recall (the label calls for a 50% dose reduction with concurrent radiation); and embryo-fetal toxicity. Live viral vaccines are not recommended before or during treatment. Common reactions include infection, hair loss, rash, nausea, vomiting, low blood counts and mouth sores.

Where it stands

Dactinomycin is an old, approved chemotherapy still in standard regimens for several childhood and gynaecological cancers. The Cosmegen brand (NDA 050682) is listed as discontinued in Drugs@FDA; four generic versions, with original approvals dated 2017–2020, are listed. Treatment decisions belong to an oncology team; this entry records what the compound is and what its label and trials state.

Not opened for this entry: the original 1960s approval documents and the history of the actinomycins' discovery; the date shown above is the oldest submission on the Drugs@FDA file, not a confirmed approval date.

Sources opened 2026-11-19: openFDA drug label (Meitheal dactinomycin for injection, effective 2020-11-13); Drugs@FDA via openFDA (NDA 050682 and four ANDAs); PubChem (CID 457193); PubMed E-utilities (count; abstracts of PMIDs 21263100, 9440748); ClinicalTrials.gov API v2.

What the research shows

Treats low-risk gestational trophoblastic neoplasia

GOG phase III trial, Osborne et al. 2011, J Clin Oncol (PMID 21263100): 216 eligible women; complete response 70% with pulsed dactinomycin v 53% with weekly methotrexate (P = .01)

Part of curative chemotherapy for Wilms tumour

NWTS-4, Green et al. 1998, J Clin Oncol (PMID 9440748): 1,687 children randomised between single-dose and divided-dose schedules; 2-year relapse-free survival 91.3% v 91.4% in the low-risk group

Binds DNA and inhibits RNA synthesis

Mechanism as stated on the label (section 12.1)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Brand Cosmegen (NDA 050682, Recordati Rare Diseases) listed as discontinued; generic dactinomycin for injection under ANDAs from Eugia (2017), XGen (2019), Hisun (2019) and Meitheal (2020) (Drugs@FDA, original-approval dates, read 2026-11-19).

How it is given

Single-dose vials of 500 mcg lyophilised powder for intravenous use; dosed per kilogram or per square metre by regimen (Meitheal label, effective 2020-11-13).

Published record

PubMed: 19,541 records for 'dactinomycin'; ClinicalTrials.gov: 83 studies (2026-11-19).

Frequently asked questions

What is dactinomycin?

A cancer chemotherapy drug made by Streptomyces bacteria. Chemically it is a chromopeptide: two rings of five amino acids attached to a flat, coloured core. It is also called actinomycin D.

Why is dactinomycin in a peptide library?

Because its two rings are peptides. Each is a chain of five amino acids closed into a ring and attached to the drug's flat core, so it sits in the library's class of peptide-derived antibiotics alongside bleomycin.

What is dactinomycin used for?

The label lists Wilms tumour, rhabdomyosarcoma, Ewing sarcoma and metastatic nonseminomatous testicular cancer in combination regimens, gestational trophoblastic neoplasia, and regional perfusion with melphalan for some recurrent solid tumours.

What doses does the label state?

They vary by cancer. The label gives, for example, 45 mcg/kg once every 3 to 6 weeks in Wilms tumour regimens and 12 mcg/kg daily for five days as a single agent in low-risk gestational trophoblastic neoplasia. Doses are set by the treating oncology team.

What are its main risks?

The label warns of secondary cancers including leukaemia, severe or fatal liver veno-occlusive disease (higher risk under age 4 or with radiotherapy), tissue damage if it leaks from the vein, low blood counts, severe skin and mouth reactions, kidney and liver toxicity, worsening of radiation effects and harm to a fetus.

Is Cosmegen still sold?

Drugs@FDA lists the Cosmegen brand as discontinued. Generic dactinomycin for injection from four manufacturers is listed as a prescription drug.